

1. (Amended) A method for producing a virus and/or viral proteins other than adenovirus or adenoviral proteins for use as a vaccine, said method comprising:

providing a cell with at least a sequence encoding at least one gene product of the E1 gene or a functional derivative thereof of an adenovirus,

providing said cell with a nucleic acid encoding said non-adenoviral virus and/or said non-adenoviral viral proteins,

culturing said cell in a suitable medium and allowing for expression of said non-adenoviral virus and/or said non-adenoviral viral proteins, and

harvesting said non-adenoviral virus and/or non-adenoviral viral proteins from said suitable medium and/or said cell.

2. (Amended) [A]The method according to claim 1, wherein said cell is a human primary cell.

3. (Amended) [A]The method according to claim 1 [or 2,] wherein said human primary cell is immortalized by a gene product of [said]the E1 gene.

4. (Amended) [A]The method according to [any one of claims 1-3,]claim 2 wherein said cell is derived from a human embryonic retinoblast.

5. (Amended) [A]The method according to [anyone of claims 1-4,]claim 2 wherein said sequence encoding at least one gene product of the E1 gene is present in the genome of said human primary cell.

6. (Amended) [A]The method according to [anyone of claims 1-5,]claim 1 wherein said cell does not produce adenoviral structural proteins.

7. (Amended) [A]The method according to [any one of the foregoing claims,]claim 2 wherein said cell further comprises a sequence encoding E2A or a functional derivative or analogue or fragment thereof.

8. (Amended) [A]The method according to [anyone of the foregoing claims]claim 7 wherein said sequence encoding E2A or a functional derivative or analogue or fragment thereof, is present in the genome of said human primary cell.

9. (Amended) [A]The method according to [any one of claims 7 or 8,]claim 7 wherein said E2A encoding sequence encodes the temperature sensitive mutant E2A.

10. (Amended) [A]The method according to [any one of the foregoing claims whereby]claim 2 wherein said human primary cell comprises no other adenoviral sequences

11. (Amended)[A]The method according to [anyone of the foregoing claims,]claim 2 wherein said human primary cell is [capable of growing]grown in suspension.

12. (Amended) [A]The method according to [anyone of the foregoing claims]claim 2 wherein said human primary cell [can be]is cultured in the absence of serum.

13. (Amended) [A]The method according to [anyone of the foregoing claims]claim 2 wherein said human cell is PER.C6 as deposited under ECACC no. 96022940 or derivative thereof.

14. (Amended) [A]The method according to [any one of claims 1-13,]claim 1 wherein said virus and/or said viral proteins comprise a protein that undergoes post-translational and/or peritranslational modifications.

15. (Amended) [A]The method according to claim 14 wherein said post-translational and/or peritranslational modifications comprise glycosylation of a viral protein.

16. (Amended) [A]The method according to any one of the foregoing claims wherein said viral proteins comprise at least one of an Influenza virus neuramidase or a hemagglutinin.

A1
17. (Amended) [A]The method according to [any one of claims 1-16,]claim 1 wherein said non-adenoviral virus is [enterovirus, such as rhinovirus, aphtovirus, or poliomyelitis virus]selected from the group of non-adenoviral viruses consisting of enterovirus, rhinovirus, aphtovirus, poliomyelitis virus herpesvirus, herpes simplex virus, pseudorabies virus, bovine herpes virus, orthomyxovirus, influenza virus, paramyxovirus, New Castle disease virus, respiratory syncitio virus, mumps virus, measles virus, retrovirus, human immunodeficiency virus, parvovirus, papavovirus, rotavirus, coronavirus, transmissible gastroenteritis virus, flavivirus, tick-borne encephalitis virus, yellow fever virus, togavirus, rubella virus, Eastern equine encephalomyelitis virus, Western equine encephalomyelitis virus, Venezuelan equine encephalomyelitis virus, hepatitis causing virus, hepatitis A virus, hepatitis B virus, pestivirus, hog cholera virus, rhabdovirus, and rabies virus.

Please cancel claims 18 through 24 without prejudice or disclaimer.

A2
25. (Amended) [Use of]An improvement in a process for producing a non-adenoviral virus or viral protein for use in a vaccine for use in a human subject, said process being of the type wherein a cell line is infected with a virus, the improvement comprising: using, as the cell line in the process, a human cell having a sequence encoding at least one E1 protein of an adenovirus or a functional derivative, homologue or fragment thereof in its genome, which human cell does not produce structural adenoviral proteins [for the production of a virus or at least one viral protein for use in a vaccine].

26. (Amended) [Use according to]The improvement of claim 25, wherein said human cell is derived from a primary cell.

27. (Amended) [Use according to]The improvement of claim 25 [or 26], wherein said human cell is a PER.C6 cell or a derivative thereof.

28. (Amended) [Use according to claim 25-27,] The improvement of claim 25 wherein said human cell further comprises a sequence encoding adenoviral E2A or a functional derivative or analogue or fragment thereof in its genome.

29. (Amended) [Use according to] The improvement of claim 28, wherein said adenoviral E2A is temperature sensitive.

30. (Amended) A non-adenoviral virus or non-adenoviral viral protein for use a vaccine [obtainable by method according to any one of claims 1-24 or by a use according to any one of claims 25-29,] produced by the process of claim 1, said virus or said viral being free of any non-human mammalian proteinaceous material.

31. (Amended) A human cell having a sequence encoding at least one E1 protein of an adenovirus or a functional derivative, homologue or fragment thereof in its genome, which human cell does not produce structural adenoviral proteins, and said human cell further having a nucleic acid encoding a virus or at least one non-adenoviral viral protein.

32. (Amended) [A] The human cell [according to] of claim 31 which is derived from PER.C6 as deposited under ECACC no. 96022940.

33. (Amended) [A] The human cell [according to] of claim [31-32] 31, which further comprises a sequence encoding adenoviral E2A or a functional derivative or analogue or fragment thereof in [its] the human cell's genome.

34 (Amended) [A] The human cell [according to] of claim 33, wherein said adenoviral E2A is temperature sensitive.